Loading…
Loading…
See exactly how RSPH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RSPH and 80,000+ other tickers.
The Invesco S&P 500 Equal Weight Health Care ETF aims to track the performance of the S&P 500 Equal Weight Health Care Index. This fund primarily allocates a minimum of 90% of its total assets to the common stocks that constitute its underlying benchmark. The Index itself assigns an equal weighting to all healthcare sector companies that are part of the broader S&P 500 Index. Both the ETF and the Index undergo a portfolio adjustment process on a quarterly basis.
PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.
The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) was launched on 11/01/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Invesco Nasdaq Biotechnology ETF has a lower expense ratio but higher price volatility than Invesco S&P 500 Equal Weight Health Care ETF. Invesco S&P 500 Equal Weight Health Care ETF holds fewer stocks but uses an equal-weighting strategy to diversify across the large-cap healthcare sector.